RETIREMENT AND SEPARATION AGREEMENTRetirement and Separation Agreement • January 11th, 2016 • Oncothyreon Inc. • Services-commercial physical & biological research • Washington
This Retirement and Separation Agreement (the “Agreement”) is entered into by and between ONCOTHYREON INC., a Delaware Corporation, (the “Company”) and ROBERT KIRKMAN, M.D. (“Executive”) (each of Executive and the Company, a “Party,” and collectively, the “Parties”). This Agreement shall become effective (the “Effective Date”) on January 11, 2016.
January 11, 2016 BVF Partners L.P. Biotechnology Value Fund, L.P. Biotechnology Value Fund II, L.P. BVF Inc. One Sansome Street, 30th Floor San Francisco, CA 94104 Biotechnology Value Trading Fund OS, L.P. BVF Partners OS Ltd. PO Box 309 Ugland House...Oncothyreon Inc. • January 11th, 2016 • Services-commercial physical & biological research • Delaware
In exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Oncothyreon Inc., a Delaware corporation (the “Company”), and each of BVF Partners L.P. (“BVF”), Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., BVF Partners OS Ltd. and BVF Inc. (each, individually, a “Stockholder” and, collectively, the “Stockholders”), agree as follows:
